Alexander Kalin

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment

Angela Genge, Gary L. Pattee, Gen Sobue et al. · Muscle & Nerve · 2022 · 24 citations · Full text

A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies

Alexander Kalin, Elvia Medina-Paraiso, Kaoru Ishizaki et al. · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2017 · 20 citations · Full text

Analysis of the US Safety Data for Edaravone (Radicava®) From the Third Year After Launch

Angela Genge, Benjamin Rix Brooks, Björn Oskarsson et al. · Drugs in R&D · 2022 · 17 citations · Full text